About: Influenza vaccine effectiveness estimates in the Dutch population from 2003 to 2014: The test-negative design case-control study with different control groups

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Influenza vaccine effectiveness estimates in the Dutch population from 2003 to 2014: The test-negative design case-control study with different control groups Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Influenza vaccine effectiveness estimates in the Dutch population from 2003 to 2014: The test-negative design case-control study with different control groups
Creator	Dijkstra, Frederika Meijer, Adam Donker, Gé Darvishian, Maryam Hak, Eelko Overduin, Pieter Van Doorn, Eva
source	Elsevier; Medline; PMC
abstract	Abstract Information about influenza vaccine effectiveness (IVE) is important for vaccine strain selection and immunization policy decisions. The test-negative design (TND) case-control study is commonly used to obtain IVE estimates. However, the definition of the control patients may influence IVE estimates. We have conducted a TND study using the Dutch Sentinel Practices of NIVEL Primary Care Database which includes data from patients who consulted the General Practitioner (GP) for an episode of acute influenza-like illness (ILI) or acute respiratory infection (ARI) with known influenza vaccination status. Cases were patients tested positive for influenza virus. Controls were grouped into those who tested (1) negative for influenza virus (all influenza negative), (2) negative for influenza virus, but positive for respiratory syncytial virus, rhinovirus or enterovirus (non-influenza virus positive), and (3) negative for these four viruses (pan-negative). We estimated the IVE over all epidemic seasons from 2003/2004 through 2013/2014, pooled IVE for influenza vaccine partial/full matched and mismatched seasons and the individual seasons using generalized linear mixed-effect and multiple logistic regression models. The overall IVE adjusted for age, GP ILI/ARI diagnosis, chronic disease and respiratory allergy was 35% (95% CI: 15–48), 64% (95% CI: 49–75) and 21% (95% CI: −1 to 39) for all influenza negative, non-influenza virus positive and pan-negative controls, respectively. In both the main and subgroup analyses IVE estimates were the highest using non-influenza virus positive controls, likely due to limiting inclusion of controls without laboratory-confirmation of a virus causing the respiratory disease.
has issue date	2017-05-15(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2017.04.012
bibo:pmid	28412077
has license	els-covid
sha1sum (hex)	d05bd9b2a6536a3a64fb6156fc3fc116ec577625
schema:url	https://doi.org/10.1016/j.vaccine.2017.04.012
resource representing a document's title	Influenza vaccine effectiveness estimates in the Dutch population from 2003 to 2014: The test-negative design case-control study with different control groups
has PubMed Central identifier	PMC7126814
has PubMed identifier	28412077
schema:publication	Vaccine
resource representing a document's body	covid:d05bd9b2a6536a3a64fb6156fc3fc116ec577625#body_text
is schema:about of	named entity 'INFLUENZA VACCINE' named entity 'limiting' named entity 'IVE' named entity 'policy' named entity 'tested' named entity 'General Practitioner' named entity 'strain' named entity '2004' named entity 'DESIGN' named entity 'USED' named entity 'RHINOVIRUS' named entity 'VACCINE EFFECTIVENESS' named entity 'CASES' named entity 'PRACTICES' named entity 'ADJUSTED FOR AGE' named entity '283' named entity 'EFFECT' named entity 'IMMUNIZATION' named entity 'CONSULTED' named entity 'PRIMARY CARE' named entity 'NEGATIVE' named entity 'STUDY' named entity 'INDIVIDUAL' named entity 'VACCINE STRAIN' named entity 'ILI' named entity 'ESTIMATES' named entity 'MULTIPLE LOGISTIC REGRESSION MODELS' named entity 'BUT' named entity 'INFLUENCE' named entity 'DATA' named entity 'PARTIAL' named entity 'SELECTION' named entity 'LIMITING' named entity 'CHRONIC DISEASE' named entity 'DUTCH' named entity 'POOLED' named entity 'DECISIONS' named entity 'EPIDEMIC' named entity 'CASE-CONTROL STUDY' named entity 'GROUPED' named entity 'TEST' named entity 'RESPIRATORY SYNCYTIAL VIRUS' named entity 'IMPORTANT' named entity 'DATABASE' named entity 'LABORATORY' named entity 'MAIN' named entity 'INFLUENZA VACCINATION STATUS' named entity 'CONFIRMATION OF' named entity 'VIRUSES' named entity 'LIKELY' named entity 'DUE TO' named entity 'INFLUENZA-LIKE ILLNESS' named entity 'PAN' named entity 'SEASONS' named entity 'INFORMATION' named entity 'RESPIRATORY ALLERGY' named entity 'KNOWN' named entity 'HAVE' named entity 'PATIENTS' named entity 'NEGATIVE' named entity 'ESTIMATES' named entity 'RESPIRATORY DISEASE' named entity 'VIRUS' named entity 'INFLUENZA VACCINE' named entity '282' named entity 'DUTCH POPULATION' named entity 'VACCINE EFFECTIVENESS' named entity 'CONTROL GROUPS' named entity 'TEST' named entity 'MIXED' named entity 'DIAGNOSIS' named entity 'CAUSING' named entity 'INFLUENZA' named entity 'SUBGROUP' named entity 'MATCHED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software